Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1650 • ACR Convergence 2022
Systemic Immune Inflammation Index Predict All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis
Jose felix Restrepo Suarez¹, Inmaculada Del Rincon¹, Carlos Lorenzo² and Agustin Escalante³, ¹University of Texas Health Science center at San Antonio, San Antonio, TX, ²University of Texas Health Sciences Center San Antonio, San antonio, TX, ³University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: The systemic immune inflammation index (SII) is an inflammation-based biomarker that is an influential prognostic factor in diseases with an inflammation-related etiology. This index…
Abstract Number: 1749 • ACR Convergence 2022
Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis
Eddie James¹, Cliff Rims², Sylvia Posso², Jeffrey Carlin³, William Kwok², Shao-En Ong⁴ and Jane Buckner¹, ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease in which citrullinated self-antigens are recognized by anti-citrullinated protein antibodies (ACPA) and T cells. ACPA are a…
Abstract Number: 1950 • ACR Convergence 2022
Morbidities Associated with Serious Infections in Patients with Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Ryan Lennon³, John Davis³ and Elena Myasoedova³, ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for serious infections. Several infection risk scores have been developed over the last decade for…
Abstract Number: 1966 • ACR Convergence 2022
Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Eva van Geel¹, Bafrin Abdulmajid¹, Annelies Blanken² and Michael Nurmohamed³, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Amsterdam University Medical Center, Kortenhoef, Netherlands
Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…
Abstract Number: 1984 • ACR Convergence 2022
Malignancies Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION Study
jacques-eric gottenberg¹, Nadir Mammar², Meriem Kessouri², Jeremie RUDANT², nada Assi³, Fanny raguideau³ and julien kirchgesner⁴, ¹Strasbourg University Hospital, Strasbourg, France, ²Pfizer, Paris, France, ³HEVA, Lyon, France, ⁴AP-HP, Paris, France
Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis RA, are at increased risk of cancer compared with the general population. It is hence…
Abstract Number: 2001 • ACR Convergence 2022
Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
Tanya Shivacheva, Medical University prof.dr. P. Stoyanov, Varna, Bulgaria, Varna, Bulgaria
Background/Purpose: Sustained targeted therapeutic outcome with biological therapy in real clinical conditions is not yet achievable in a large proportion of rheumatoid arthritis (RA) patients.…
Abstract Number: 2147 • ACR Convergence 2022
Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study
Filipe Pinheiro¹, Rui Gaspar², Bruno Fernandes³, Armando Peixoto², Guilherme Macedo² and Iva Brito⁴, ¹Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ²Gastroenterology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, ³Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁴Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal
Background/Purpose: Methotrexate is an immunomodulatory agentu sed in several inflammatory diseases, such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or inflammatory bowel disease (IBD). Despite being…
Abstract Number: 2220 • ACR Convergence 2022
Recurrence of Herpes Zoster Reactivation After Events of Herpes Zoster in Patients Receiving JAK Inhibitors in South Korea: A Nationwide Population-based Study
YoungEun Kim¹, Ye-Jee Kim², Seonok Kim², Soo Min Ahn¹, Ji Seon Oh³, Yong Gil Kim¹, Chang Keun Lee¹, Bin Yoo¹, Sang Hyoung Park⁴ and Seokchan Hong¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ³Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea, ⁴Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea
Background/Purpose: Janus kinase (JAK) inhibitors are known to increase the risk of herpes zoster (HZ) reactivation; however, studies on the risk of HZ recurrence when…
Abstract Number: PP21 • ACR Convergence 2022
What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work
Shilpa Venkatachalam, Global Healthy Living Foundation, New York, NY
Background/Purpose: When I first received my Rheumatoid Arthritis (RA) diagnosis 5 years ago, I experienced a combination of relief and disbelief. Relief because now all…
Abstract Number: 0049 • ACR Convergence 2022
IL-18 Receptor-α Signaling Pathway Contributes to Autoantibody-induced Arthritis via Neutrophil Recruitment
Shinjiro Kaieda and Tomoaki Hoshino, Kurume University School of Medicine, Kurume, Japan
Background/Purpose: We have previously reported that IL-18 levels in the lungs, serum and bronchoalveolar lavage fluid (BALF) were increased in patients with idiopathic pulmonary lung…
Abstract Number: 0093 • ACR Convergence 2022
Comparison of Faculty and Fellow Prescribing Patterns for Rheumatoid Arthritis in an Urban, Academic Hospital
Ana Valle¹, Xianhong Xie², Don-Andre Jackson³ and Irene Blanco⁴, ¹Montefiore Medical Center, New York, NY, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Griffin Health, Stamford, CT, ⁴Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Timely initiation of DMARDs in rheumatoid arthritis (RA) is necessary to prevent significant morbidity and mortality. Yet, patients from marginalized groups are less likely…
Abstract Number: 0205 • ACR Convergence 2022
Virtually Training Peer Coaches to Use Motivational Interviewing Skills: Processes from a Rheumatoid Arthritis Intervention Training Program
Mackenzie Brown¹, Yuliana Domínguez Páez², Assem Jabri³, Geyanne Lui⁴, Joan Weiner³, Aberdeen Allen⁵, Tien Sydnor-Campbell⁶, Shelley fritz³, Megan Creasman⁷, Shanthini Kasturi⁸, Monika Safford³ and Iris Navarro-Millan³, ¹Weill Cornell Medicine, Brooklyn, NY, ²Weill Cornell Medicine, Bronx, NY, ³Weill Cornell Medicine, New York, NY, ⁴Albert Einstein College of Medicine, New York, NY, ⁵Weill Cornell Medicine, Parlin, ⁶Weill Cornell Medicine, Philedelphia, ⁷NYP-Weill Cornell, New York, NY, ⁸Tufts Medical Center, Boston, MA
Background/Purpose: Peer coaching interventions are effective in helping individuals with chronic conditions understand and manage their disease. Most peer coach training programs occur in person,…
Abstract Number: 0253 • ACR Convergence 2022
Evaluation of Patients with Rheumatoid Arthritis in Teleconsultation During the First Wave of the COVID-19 Pandemic
Jérôme Avouac¹, Anna Molto², Camelia Frantz³, sarah wanono³, elise descamps⁴, olivier fogel⁴, Alice Combier⁵, lucile poiroux⁵, Corinne MIceli⁶ and Yannick Allanore⁷, ¹University of Paris, Paris, France, ²Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France, ³Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Hôpital Cochin, AP-HP Centre - Université de Paris Cité, Paris, France, ⁵Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, ⁶APHP, Paris, France, ⁷Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The sudden emergence of SARS-CoV-2 onto the world stage has accelerated a major change in the management of patients with chronic rheumatic diseases and…
Abstract Number: 0269 • ACR Convergence 2022
Practical Cut-off Points for Using the Rheumatoid Arthritis Impact of Disease (RAID) Questionnaire in Remote Consult Triage
Marijke van den Dikkenberg¹, Martijn Kuijper², Marc Kok¹, Deirisa Lopes Barreto² and Angelique Weel¹, ¹Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical immunology, Maasstad Hospital, Rotterdam
Background/Purpose: In modern Rheumatoid Arthritis (RA) care remote consults (via phone or video call) are increasing. Whereas the Disease Activity Scores (DAS) requires a patient…
Abstract Number: 0288 • ACR Convergence 2022
Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
Loïc Meudec¹, Pauline Richebé¹, Juliette Pascaud², Xavier Mariette³ and Gaetane Nocturne⁴, ¹Université Paris-Saclay, AP-HP-Hôpital Bicêtre, Le Kremlin Bicêtre, France, ²Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, ³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁴APHP, Le Kremlin Bicêtre, France
Background/Purpose: Janus kinase inhibitors (JAKi) are effective treatments licensed in rheumatoid arthritis (RA). Concerns about a risk of cancer may arise with JAKi as in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].